What is Kidney Failure?
Kidney failure, also known as end-stage renal disease (ESRD) or end-stage kidney disease (ESKD), occurs when the kidneys can no longer function well enough to meet the body's needs. At this stage, the kidneys have lost approximately 85–90% of their function, and the patient requires either dialysis or a kidney transplant to survive. Kidney failure represents the final stage (Stage 5) of chronic kidney disease (CKD).
The kidneys perform several critical functions: filtering waste products and excess fluid from the blood, regulating blood pressure through the renin-angiotensin system, producing erythropoietin to stimulate red blood cell production, activating vitamin D for bone health, and maintaining electrolyte balance. When these functions fail, toxins accumulate in the blood, fluid overload occurs, and multiple organ systems are affected.
Globally, CKD affects approximately 10–15% of the adult population, with millions progressing to kidney failure each year. Early identification of patients at high risk for progression is crucial, as timely interventions can significantly slow or even halt the decline in kidney function. This is where risk prediction tools like the Kidney Failure Risk Equation become invaluable.
CKD Progression
Chronic kidney disease typically progresses gradually over months to years. The rate of progression varies enormously between individuals — some patients remain stable for decades, while others progress to kidney failure within a few years. Understanding the factors that drive progression is essential for risk stratification and treatment planning.
The two most important predictors of CKD progression are the estimated glomerular filtration rate (eGFR) and the urine albumin-to-creatinine ratio (ACR). eGFR measures how well the kidneys filter blood, while ACR indicates the level of protein leaking into the urine — a sign of kidney damage. Together, these two measurements provide a powerful prediction of future kidney function decline.
A rapid decline in eGFR (defined as a loss of more than 5 mL/min/1.73m² per year) is considered a significant red flag for progression to kidney failure. However, even patients with slowly declining eGFR may eventually reach kidney failure if they live long enough, particularly if they have high levels of albuminuria.
The KFRE Model (Tangri 2011)
The Kidney Failure Risk Equation (KFRE) was developed by Dr. Navdeep Tangri and colleagues in 2011 and published in the Journal of the American Medical Association (JAMA). It was derived from a cohort of over 3,000 patients with CKD stages 3–5 in Canada and has since been validated in more than 30 countries across diverse populations involving over 700,000 patients.
The KFRE comes in two versions: a 4-variable model (age, sex, eGFR, ACR) and an 8-variable model that additionally includes serum calcium, phosphate, bicarbonate, and albumin. The 4-variable model, used in this calculator, has been shown to provide excellent discrimination (C-statistic of approximately 0.90) and is recommended by KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for clinical use.
The model calculates a risk score based on weighted contributions from each variable, with lower eGFR, higher ACR, male sex, and younger age all associated with higher risk of kidney failure. The resulting probability represents the estimated likelihood of progressing to kidney failure requiring dialysis or transplantation within 5 years.
A key strength of the KFRE is its ability to identify patients who are very unlikely to progress, helping avoid unnecessary referrals and interventions. For example, a 70-year-old with eGFR of 45 and normal ACR has a very low 5-year risk, whereas a 50-year-old with eGFR of 20 and high ACR faces a substantially elevated risk.
Risk Factors for Kidney Failure
- Diabetes: The leading cause of kidney failure worldwide, accounting for approximately 40% of new cases. Diabetic nephropathy develops in 20–40% of diabetics over their lifetime.
- Hypertension: The second most common cause of kidney failure. Uncontrolled high blood pressure damages the small blood vessels in the kidneys, accelerating nephron loss.
- Glomerulonephritis: A group of diseases that cause inflammation of the kidney's filtering units. IgA nephropathy, focal segmental glomerulosclerosis (FSGS), and membranous nephropathy are common subtypes.
- Polycystic Kidney Disease (PKD): A genetic condition causing fluid-filled cysts to develop in the kidneys, progressively destroying normal tissue.
- Proteinuria/Albuminuria: Protein in the urine is both a marker and a driver of kidney damage. Higher levels of albuminuria indicate worse prognosis.
- Cardiovascular Disease: Heart and kidney disease are closely linked. Heart failure reduces blood flow to the kidneys, accelerating CKD progression.
- Smoking: Smoking damages blood vessels, increases blood pressure, and has direct toxic effects on kidney tissue.
- Obesity: Excess body weight increases the kidneys' workload and is associated with hyperfiltration injury and progressive nephron loss.
- Family History: Having a first-degree relative with kidney failure increases your risk 3–9 fold.
- Recurrent Kidney Infections: Repeated pyelonephritis can cause scarring and permanent damage to kidney tissue.
CKD Stages Explained
| Stage | eGFR (mL/min/1.73m²) | Description | Action |
|---|---|---|---|
| Stage 1 | ≥ 90 | Normal or high with kidney damage markers | Monitor, treat underlying cause |
| Stage 2 | 60–89 | Mildly decreased | Estimate progression risk |
| Stage 3a | 45–59 | Mildly to moderately decreased | Monitor complications |
| Stage 3b | 30–44 | Moderately to severely decreased | Nephrology referral |
| Stage 4 | 15–29 | Severely decreased | Prepare for renal replacement |
| Stage 5 | < 15 | Kidney failure (ESRD) | Dialysis or transplant |
CKD staging also incorporates albuminuria categories: A1 (normal, ACR <30 mg/g), A2 (moderately increased, ACR 30–300 mg/g), and A3 (severely increased, ACR >300 mg/g). The combination of eGFR stage and albuminuria category determines the overall risk profile and guides management decisions.
How to Slow Progression
Multiple evidence-based interventions can significantly slow CKD progression and delay or prevent kidney failure:
- Blood Pressure Control: Target <130/80 mmHg for most CKD patients. ACE inhibitors (e.g., ramipril, lisinopril) or ARBs (e.g., losartan, valsartan) are first-line agents as they reduce intraglomerular pressure and proteinuria.
- Glycemic Control: For diabetic CKD patients, HbA1c targets of 6.5–7.5% can slow progression. SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) have shown remarkable renal protective benefits in landmark trials (DAPA-CKD, EMPA-KIDNEY).
- SGLT2 Inhibitors: These medications slow CKD progression by approximately 30–40% in both diabetic and non-diabetic CKD, and are now recommended for most patients with eGFR ≥20 and significant albuminuria.
- Dietary Modifications: Moderate protein restriction (0.6–0.8 g/kg/day), sodium restriction (<2g/day), and adequate hydration can reduce kidney workload and slow progression.
- Avoid Nephrotoxins: NSAIDs (ibuprofen, naproxen), certain antibiotics, and contrast dyes should be avoided or used cautiously in CKD patients.
- Smoking Cessation: Quitting smoking can reduce the rate of eGFR decline by 1–2 mL/min/year.
- Treat Underlying Conditions: Managing the primary cause of CKD (diabetes, glomerulonephritis, etc.) is fundamental to slowing progression.
- MRA Therapy: Non-steroidal mineralocorticoid receptor antagonists (e.g., finerenone) have shown additional benefit in diabetic CKD patients.
Risk Stratification Diagram
Frequently Asked Questions
How accurate is the Kidney Failure Risk Equation?
The 4-variable KFRE has been extensively validated across more than 30 countries and demonstrates excellent discriminative ability with a C-statistic of approximately 0.90. This means it correctly identifies the higher-risk individual in 90% of patient pairs. However, like all predictive models, it provides a probability rather than a certainty, and individual outcomes may vary.
Can kidney failure be reversed?
In most cases, chronic kidney damage is irreversible. However, acute kidney injury (AKI) can often be reversed if treated promptly. For CKD, the goal is to slow or halt progression rather than reverse existing damage. Early intervention with medications (ACE inhibitors, SGLT2 inhibitors) and lifestyle changes can stabilize kidney function for many years in some patients.
What is eGFR and how is it measured?
eGFR (estimated Glomerular Filtration Rate) is a blood test-derived estimate of how well your kidneys filter waste. It is calculated from serum creatinine (or cystatin C) levels, adjusted for age, sex, and sometimes race. A normal eGFR is above 90 mL/min/1.73m². The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation is the most widely used formula for calculating eGFR.
What does the ACR number mean?
The urine Albumin-to-Creatinine Ratio (ACR) measures how much albumin (a type of protein) is leaking into your urine. An ACR below 30 mg/g is normal, 30–300 mg/g indicates moderately increased albuminuria (formerly called microalbuminuria), and above 300 mg/g indicates severely increased albuminuria (formerly macroalbuminuria). Higher ACR values indicate more severe kidney damage and predict faster progression.
Should everyone with CKD be referred to a nephrologist?
Not necessarily. Current guidelines recommend nephrology referral when eGFR falls below 30, when there is a rapid decline in eGFR (>5 mL/min/year), when the 5-year KFRE risk exceeds 3–5%, or when there are complications such as resistant hypertension, severe electrolyte abnormalities, or unexplained kidney disease. The KFRE helps identify which patients benefit most from specialist care.
How often should kidney function be monitored?
Monitoring frequency depends on CKD stage and risk of progression. Stage 1–2 with low risk: annually. Stage 3 with moderate risk: every 6 months. Stage 4–5 or high risk of progression: every 1–3 months. Your healthcare provider will determine the appropriate monitoring schedule based on your individual risk profile and treatment response.